Navigation Links
INDIGO Biosciences Announces Record Revenue Numbers for 2019

INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, has announced a record earnings year for 2019. With final numbers to be released to Company Shareholders in the upcoming weeks, INDIGO showed more than a twenty percent increase in revenue and a thirty percent increase in gross profit, and more than 175% increase in EBITDA, all while continuing R&D efforts and completing a Company relocation.

“With the help of our customers, shareholders and team members, INDIGO provides superior products and service to the industries we serve. 2019 represented a breakout year, and we are excited about the future,” said Fred Marroni, INDIGO’s President and CEO. “We look forward to continuing to expand our product offerings, our industries served, and world-wide distribution capabilities.”

The Company, founded in 2005, is known for providing the world’s largest portfolio of nuclear receptor assay kits and services, as well as solutions for in vitro toxicology testing, for early-stage discovery testing. 2019 saw an expansion in INDIGO’s toxicology offerings with the addition of three additional testing solutions, including assays for drug-induced toxicity, multi-drug resistance, and gene expression profiling. In addition, the Company’s Science Team introduced two new animal model assays for the Farnesoid X Receptor - a nuclear receptor critical to metabolic disorder, Non-Alcoholic Fatty Liver Disease, and toxicology research.

INDIGO expanded in other ways as well in 2019, including the relocation of the Company to a new, larger facility. With expanded laboratory space and key collaboration areas, the move allowed the Company to remain in State College and provides enough space for a near doubling of capabilities and personnel in the upcoming years.

Looking Forward
The INDIGO team continues to look for methods and arenas to further grow the company in terms of both product and service offerings, as well as expanded customer and partner collaborations. The Company has already started 2020 off with the announcement of the addition of four first-in-class zebrafish model assays to their portfolio. Continued R&D efforts are anticipated to help bring additional products to market in both the cell-based assay and toxicology markets. Plans for the new year also include expanding the Science staff, and Sales and Marketing team.

About INDIGO Biosciences, Inc.
INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. INDIGO supplements the world’s largest portfolio of nuclear receptor kits and services and in vitro toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms aim to reduce the time, cost, and risk associated with the discovery process. Learn more at

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Inflection Biosciences licenses preclinical oncology programs from the CNIO
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Springer will publish lecture series with the Mathematical Biosciences Institute
4. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
5. Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
6. The new Africa -- green shoots in biosciences
7. Pressure BioSciences Closes Additional $745,000 of $5 Million PIPE; Funding Received to Date Exceeds $4,000,000
8. ACEA Biosciences Introduces an Exploratory xCELLigence® RTCA S16 Instrument
9. ACEA Biosciences Releases New Version of NovoExpress® Flow Cytometry Software.
10. ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
11. Tosoh Bioscience LLC invests in Semba Biosciences
Post Your Comments:
(Date:2/28/2020)... , ... February 28, 2020 , ... Meridian Clinical ... 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. Meridian is ... for the Best Clinical Trial Network award. These nominations were the result of two ...
(Date:2/28/2020)... ... February 27, 2020 , ... An upcoming ... treatment solutions for maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohn’s Disease ... will focus on a novel platform developed by Deka Biosciences, Inc. (Deka Biosciences), ...
(Date:2/28/2020)... ... February 27, 2020 , ... ... formed Filtravate, its newest portfolio company. Established to develop and commercialize a ... licensed from New Mexico State University (NMSU). The patent-pending technology results in ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... ... March 31, 2020 , ... ... (P2) announce the signing of a Joint Development Agreement that builds on each ... Inc. is a global leader in the supply of high-quality insect pheromones as ...
(Date:3/13/2020)... Del. (PRWEB) , ... March 12, 2020 , ... ... collaboration with the APC Microbiome Ireland SFI Research Center (APC), a pioneer in ... on the body and play a significant role in human health, based at ...
(Date:3/4/2020)... ... March 04, 2020 , ... ... of recombinant antibody products and services, today announced the launch of its ... rapidly express a large number of antibodies at 80 ml scale. All ...
(Date:2/28/2020)... ... 2020 , ... Designed primarily for laboratory and industrial use, ... thus simplifying setup, streamlining integration, and optimizing workflow. Capable of recording FHD (1080p) ... new HS Series cameras to be released. The HS Series includes cameras with ...
Breaking Biology Technology: